litlas
Log inCreate account

Laurent Mortier

Active 2000–2025

108
Papers
33,061
Citations
59
h-index
96
i10-index

Citations

Citations per year for Laurent Mortier1986: 1 citations1997: 3 citations2000: 1 citations2001: 2 citations2002: 9 citations2003: 7 citations2004: 20 citations2005: 21 citations2006: 16 citations2007: 12 citations2008: 8 citations2009: 21 citations2010: 16 citations2011: 14 citations2012: 27 citations2013: 62 citations2014: 81 citations2015: 281 citations2016: 568 citations2017: 665 citations2018: 727 citations2019: 1,993 citations2020: 1,948 citations2021: 1,791 citations2022: 1,395 citations2023: 949 citations2024: 1,390 citations2025: 574 citations2026: 8 citations1987–1996: no citations, so these years are not shown1998–1999: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,509 citing papers, 24.2% of this breakdownChina: 1,488 citing papers, 10.2% of this breakdownItaly: 924 citing papers, 6.4% of this breakdownGermany: 895 citing papers, 6.2% of this breakdownFrance: 895 citing papers, 6.2% of this breakdownUnited Kingdom: 721 citing papers, 5% of this breakdownAustralia: 706 citing papers, 4.9% of this breakdownNetherlands: 514 citing papers, 3.5% of this breakdownJapan: 460 citing papers, 3.2% of this breakdownSpain: 451 citing papers, 3.1% of this breakdownSwitzerland: 430 citing papers, 3% of this breakdownCanada: 400 citing papers, 2.7% of this breakdown
0%24.2%Other 21.4%

Institutions

Fields

  • Medicine66.4%
  • Biochemistry, Genetics and Molecular Biology21.8%
  • Immunology and Microbiology6.8%
  • Engineering1.3%
  • Nursing0.8%
  • Computer Science0.5%
  • Other2.4%

Topics

  • Cancer Immunotherapy and Biomarkers17.2%
  • Immunotherapy and Immune Responses7.2%
  • Melanoma and MAPK Pathways6.3%
  • CAR-T cell therapy research6.1%
  • Cutaneous Melanoma Detection and Management5.2%
  • Immune Cell Function and Interaction2.5%
  • Other55.5%

Coauthors

All papers

Open in search
  1. Pembrolizumab versus Ipilimumab in Advanced Melanoma

    Authors: Caroline Robert, Jacob Schachter, Georgina V. Long, Ana Arance, Jean‐Jacques Grob, Laurent Mortier, Adil Daud, Matteo S. Carlino, Catriona M. McNeil, Michal Lotem, James Larkin, Paul Lorigan, Bart Neyns, Christian U. Blank, Omid Hamid, Christine Mateus, Ronnie Shapira‐Frommer, Michele Kosh, Honghong Zhou, Nageatte Ibrahim, Scot Ebbinghaus, Antoni Ribas - New England Journal of Medicine 2015 cited by 5,847

  2. Nivolumab in Previously Untreated Melanoma without BRAF Mutation

    Authors: Caroline Robert, Georgina V. Long, Benjamin Brady, Caroline Dutriaux, Michele Maio, Laurent Mortier, Jessica C. Hassel, Piotr Rutkowski, Catriona M. McNeil, Ewa Kalinka‐Warzocha, Kerry J. Savage, Micaela Hernberg, Célèste Lebbé, J. Charles, Catalin Mihalcioiu, Vanna Chiarion‐Sileni, Cornelia Mauch, Francesco Cognetti, Ana Arance, Henrik Schmidt, Dirk Schadendorf, Helen Gogas, L. Lundgren-Eriksson, Christine E. Horak, Brian J. Sharkey, Ian M. Waxman, Victoria Atkinson, Paolo A. Ascierto - New England Journal of Medicine 2014 cited by 5,352

  3. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

    Authors: Jeffrey S. Weber, Mario Mandalà, Michele Del Vecchio, Helen Gogas, Ana Arance, C. Lance Cowey, Stéphane Dalle, Michael Schenker, Vanna Chiarion‐Sileni, Iván Márquez‐Rodas, Jean-Jacques Grob, Marcus O. Butler, Mark R. Middleton, Michele Maio, Victoria Atkinson, Paola Queirolo, René González, Ragini R. Kudchadkar, Michael Smylie, Nicolás Meyer, Laurent Mortier, Michael B. Atkins, Georgina V. Long, Shailender Bhatia, Célèste Lebbé, Piotr Rutkowski, Kenji Yokota, Naoya Yamazaki, Tae M. Kim, Veerle de Pril, Javier Sabater, Anila Qureshi, James Larkin, Paolo A. Ascierto - New England Journal of Medicine 2017 cited by 2,207

  4. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

    Authors: Caroline Robert, Antoni Ribas, Jacob Schachter, Ana Arance, Jean‐Jacques Grob, Laurent Mortier, Adil Daud, Matteo S. Carlino, Catriona M. McNeil, Michal Lotem, James Larkin, Paul Lorigan, Bart Neyns, Christian U. Blank, Teresa M. Petrella, Omid Hamid, Shu-Chih Su, Clemens Krepler, Nageatte Ibrahim, Georgina V. Long - The Lancet Oncology 2019 cited by 1,153

  5. Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

    Authors: Caroline Robert, Bogusława Karaszewska, Jacob Schachter, Piotr Rutkowski, Andrzej Maćkiewicz, D. Stroiakovski, M. Lichinitser, Reinhard Dummer, Florent Grange, Laurent Mortier, Vanna Chiarion‐Sileni, Kamil Drucis, Ivana Krajsová, Axel Hauschild, Paul Lorigan, Pascal Wolter, Georgina V. Long, Keith T. Flaherty, Paul Nathan, Antoni Ribas, Anne-Marie Martin, Peng Sun, Wendy Crist, Jeff Legos, Stephen D. Rubin, Shonda M Little, Dirk Schadendorf - New England Journal of Medicine 2014 cited by 2,655

  6. Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced Melanoma

    Authors: Steven O’Day, Alexander M.M. Eggermont, Vanna Chiarion‐Sileni, Richard Kefford, Jean‐Jacques Grob, Laurent Mortier, Caroline Robert, Jacob Schachter, Alessandro Testori, Jacek Mackiewicz, Philip Friedlander, Claus Garbe, Selma Ugurel, Frances A. Collichio, Wei Guo, Joelle Lufkin, Safi R. Bahcall, Vojo Vukovic, Axel Hauschild - Journal of Clinical Oncology 2013 cited by 386

  7. Adjuvant Dabrafenib plus Trametinib in Stage IIIBRAF-Mutated Melanoma

    Authors: Georgina V. Long, Axel Hauschild, Mario Santinami, Victoria Atkinson, Mario Mandalà, Vanna Chiarion‐Sileni, James Larkin, Marta Nyakas, Caroline Dutriaux, Andrew Haydon, Caroline Robert, Laurent Mortier, Jacob Schachter, Dirk Schadendorf, Thierry Lesimple, Ruth Plummer, Ran Ji, Pingkuan Zhang, Bijoyesh Mookerjee, Jeff Legos, Richard Kefford, Reinhard Dummer, John M. Kirkwood - New England Journal of Medicine 2017 cited by 1,475

  8. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

    Authors: Jacob Schachter, Antoni Ribas, Georgina V. Long, Ana Arance, Jean‐Jacques Grob, Laurent Mortier, Adil Daud, Matteo S. Carlino, Catriona M. McNeil, Michal Lotem, James Larkin, Paul Lorigan, Bart Neyns, Christian U. Blank, Teresa M. Petrella, Omid Hamid, Honghong Zhou, Scot Ebbinghaus, Nageatte Ibrahim, Caroline Robert - The Lancet 2017 cited by 1,239

  9. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial

    Authors: Michael A. Davies, Philippe Saïag, Caroline Robert, Jean‐Jacques Grob, Keith T. Flaherty, Ana Arance, Vanna Chiarion‐Sileni, L. Thomas, Thierry Lesimple, Laurent Mortier, Stergios J. Moschos, David Hogg, Iván Márquez‐Rodas, Michele Del Vecchio, Célèste Lebbé, Nicolás Meyer, Ying Zhang, Yingjie Huang, Bijoyesh Mookerjee, Georgina V. Long - The Lancet Oncology 2017 cited by 775

  10. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

    Authors: Alexander Eggermont, Christian U. Blank, Mario Mandalà, Georgina V Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger H.T. Koornstra, Leonel F. Hernandez‐Aya, Anna Maria Di Giacomo, Alfons J.M. van den Eertwegh, Jean‐Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul Lorigan, Alexander C. J. van Akkooi, Clemens Krepler, Nageatte Ibrahim, Sandrine Marréaud, Michal Kiciński, Stefan Suciu, Caroline Robert, Alex Menzies, Thierry Lesimple, Michele Maio, Gerald P. Linette, Michael P. Brown, Peter Hersey, Inge Marie Svane, Laurent Mortier, Jacob Schachter, Catherine Barrow, Ragini R. Kudchadkar, Xinni Song, Caroline Dutriaux, Pietro Quaglino, Friedegund Meier, Paola Queirolo, Daniil Stroyakovskiy, Lars Bastholt, B. Guillot, Claus Garbe, Pablo L. Ortiz‐Romero, Florent Grange, Peter Mohr, Alain P. Algazi, Oliver Bechter, Micaela Hernberg, Jean‐Philippe Arnault, Philippe Saïag, Carmen Loquai, Frank Meiß, Jan‐Christoph Simon, Gil Bar‐Sela, Vanna Chiarion‐Sileni, Bernard M. Fitzharris, Mike McCrystal, Phillip Parente, Jean‐François Baurain, P. Combemale, Célèste Lebbé, Axel Hauschild, Naoya Yamazaki, Reinhard Dummer, Mohammed Milhem, Marcin Dzienis, John Walker, L. Geoffrois, M.‐T. Leccia, Lutz Kretschmer, Daniel Hendler, Michal Lotem, Andrzej Maćkiewicz, Lidija Kandolf Sekulović, Elaine Dunwoodie, Christoph Höeller, L. Machet, Jessica C. Hassel, Geke A.P. Hospers, Maria-Jose Passos, Max Levin, Martin Fehr, Philippa Corrie, Ashita Waterston, Sigrun Hallmeyer, Henrik Schmidt, V. Descamps, J.‐P. Lacour, Carola Berking, Felix Kiecker, Pier Francesco Ferrucci and 32 more - The Lancet Oncology 2021 cited by 389

  11. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

    Authors: Alexander M.M. Eggermont, Vanna Chiarion‐Sileni, Jean‐Jacques Grob, Reinhard Dummer, Jedd D. Wolchok, Henrik Schmidt, Omid Hamid, Caroline Robert, Paolo A. Ascierto, Jon Richards, Célèste Lebbé, Virginia Ferraresi, Michael Smylie, Jeffrey S. Weber, Michele Maio, Lars Bastholt, Laurent Mortier, L. Thomas, Saad Tahir, Axel Hauschild, Jessica C. Hassel, F. Stephen Hodi, Corina Taitt, Veerle de Pril, Gaetan de Schaetzen, Stefan Suciu, Alessandro Testori - New England Journal of Medicine 2016 cited by 1,313

  12. Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial

    Authors: Célèste Lebbé, Nicolás Meyer, Laurent Mortier, Iván Márquez‐Rodas, Caroline Robert, Piotr Rutkowski, Alexander M. Menzies, Thomas Eigentler, Paolo A. Ascierto, Michael Smylie, Dirk Schadendorf, Mazhar Ajaz, Inge Marie Svane, René González, Linda Rollin, Jennifer Lord‐Bessen, Abdel Saci, E. Grigoryeva, Jacopo Pigozzo - Journal of Clinical Oncology 2019 cited by 398

  13. Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma

    Authors: Reinhard Dummer, Axel Hauschild, Mario Santinami, Victoria Atkinson, Mario Mandalà, John M. Kirkwood, Vanna Chiarion‐Sileni, James Larkin, Marta Nyakas, Caroline Dutriaux, Andrew Haydon, Caroline Robert, Laurent Mortier, Jacob Schachter, Thierry Lesimple, Ruth Plummer, Kohinoor Dasgupta, Eduard Gasal, Monique Tan, Georgina V. Long, Dirk Schadendorf - New England Journal of Medicine 2020 cited by 407

  14. Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma

    Authors: Caroline Robert, Georgina V. Long, Benjamin Brady, Caroline Dutriaux, Anna Maria Di Giacomo, Laurent Mortier, Piotr Rutkowski, Jessica C. Hassel, Catriona M. McNeil, Ewa Kalinka‐Warzocha, Célèste Lebbé, J. Charles, Micaela Hernberg, Kerry J. Savage, Vanna Chiarion‐Sileni, Catalin Mihalcioiu, Cornelia Mauch, Ana Arance, Francesco Cognetti, Lars Ny, Henrik Schmidt, Dirk Schadendorf, Helen Gogas, Jesús Zoco, Sandra Re, Paolo A. Ascierto, Victoria Atkinson - Journal of Clinical Oncology 2020 cited by 227

  15. Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma

    Authors: Georgina V. Long, Axel Hauschild, Mario Santinami, John M. Kirkwood, Victoria Atkinson, Mario Mandalà, Barbara Merelli, Vanna Chiarion‐Sileni, Marta Nyakas, Andrew Haydon, Caroline Dutriaux, Caroline Robert, Laurent Mortier, Jacob Schachter, Dirk Schadendorf, Thierry Lesimple, Ruth Plummer, James Larkin, Monique Tan, Sachin Bajirao Adnaik, Paul Burgess, Tarveen Jandoo, Reinhard Dummer - New England Journal of Medicine 2024 cited by 125

  16. Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial

    Authors: Brett Hughes, E. Munoz-Couselo, Laurent Mortier, Å. Bratland, Ralf Gutzmer, Osama Roshdy, René González Mendoza, Jacob Schachter, Ana Arance, Florent Grange, Nicolás Meyer, Abhishek Joshi, Salem Billan, P. Zhang, B. Gumuscu, Ramona F. Swaby, Jean‐Jacques Grob - Annals of Oncology 2021 cited by 200

  17. First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study

    Authors: Sandra P. D’Angelo, Célèste Lebbé, Laurent Mortier, Andrew S. Brohl, Nicola Fazio, Jean‐Jacques Grob, Natalie Prinzi, Glenn J. Hanna, Jessica C. Hassel, Felix Kiecker, Sara Georges, Barbara Ellers‐Lenz, Parantu K. Shah, Gülseren Güzel, Paul Nghiem - Journal for ImmunoTherapy of Cancer 2021 cited by 140

  18. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study

    Authors: for the ERIVANCE BCC Investigators, Aleksandar Sekulić, Michael R. Migden, Nicole Basset‐Séguin, Claus Garbe, Anja Gesierich, Christopher D. Lao, Chris Miller, Laurent Mortier, Dédée F. Murrell, Omid Hamid, J. Fernando Quevedo, Jeannie Hou, Edward McKenna, Natalie Dimier, Sarah Williams, Dirk Schadendorf, Axel Hauschild - BMC Cancer 2017 cited by 412

  19. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

    Authors: Paolo A. Ascierto, Michele Del Vecchio, Caroline Robert, Andrzej Maćkiewicz, Vanna Chiarion‐Sileni, Ana Arance, Célèste Lebbé, Lars Bastholt, Omid Hamid, Piotr Rutkowski, Catriona M. McNeil, Claus Garbe, Carmen Loquai, Brigitte Dréno, L. Thomas, Jean-Jacques Grob, Gabriella Liszkay, Marta Nyakas, Ralf Gutzmer, Joanna Pikiel, Florent Grange, Christoph Höeller, Virginia Ferraresi, Michael Smylie, Dirk Schadendorf, Laurent Mortier, Inge Marie Svane, Delphine Hennicken, Anila Qureshi, Michele Maio - The Lancet Oncology 2017 cited by 495

  20. Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease

    Authors: Lysiane Marthey, Christine Mateus, Charlotte Mussini, Maria Nachury, Stéphane Nancey, Florent Grange, Camille Zallot, Laurent Peyrin‐Biroulet, Jean‐François Rahier, Mario Beauregard, Laurent Mortier, Clélia Coutzac, Émilie Soularue, Émilie Lanoy, Nathalie Kapel, David Planchard, Nathalie Chaput, Caroline Robert, Franck Carbonnel - Journal of Crohn s and Colitis 2016 cited by 342

  21. Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy

    Authors: Paolo A. Ascierto, Georgina V. Long, Caroline Robert, Benjamin Brady, Caroline Dutriaux, Anna Maria Di Giacomo, Laurent Mortier, Jessica C. Hassel, Piotr Rutkowski, Catriona M. McNeil, Ewa Kalinka‐Warzocha, Kerry J. Savage, Micaela Hernberg, Célèste Lebbé, J. Charles, Catalin Mihalcioiu, Vanna Chiarion‐Sileni, Cornelia Mauch, Francesco Cognetti, Lars Ny, Ana Arance, Inge Marie Svane, Dirk Schadendorf, Helen Gogas, Abdel Saci, Joel Jiang, Jasmine I. Rizzo, Victoria Atkinson - JAMA Oncology 2018 cited by 345

  22. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

    Authors: Georgina V. Long, Uwe Trefzer, Michael A. Davies, Richard Kefford, Paolo A. Ascierto, Paul B. Chapman, Igor Puzanov, Axel Hauschild, Caroline Robert, Alain P. Algazi, Laurent Mortier, Hussein A. Tawbi, Tabea Wilhelm, Lisa Zimmer, Julie Switzky, S. Swann, Anne-Marie Martin, Mary Guckert, Vicki Goodman, Michael Streit, John M. Kirkwood, Dirk Schadendorf - The Lancet Oncology 2012 cited by 908

  23. Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial

    Authors: Nicole Basset‐Séguin, Axel Hauschild, Rainer Kunstfeld, Jean‐Jacques Grob, Brigitte Dréno, Laurent Mortier, Paolo A. Ascierto, Lisa Licitra, Caroline Dutriaux, L. Thomas, Nicolás Meyer, B. Guillot, Reinhard Dummer, Petr Arenberger, Kate Fife, A. Raimundo, Emi Dika, Natalie Dimier, A. Fittipaldo, Ioannis Xynos, Johan Hansson - European Journal of Cancer 2017 cited by 284

  24. Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study)

    Authors: Nicolas Bertrand, P. Guerreschi, Nicole Basset‐Séguin, Philippe Saïag, A. Dupuy, S. Dalac‐Rat, Véronique Dziwniel, C. Depoortere, Alain Duhamel, Laurent Mortier - EClinicalMedicine 2021 cited by 92